A phase II study of cabozantinib and androgen ablation in patients with hormone-naïve metastatic prostate cancer

Paul G. Corn, Miao Zhang, Graciela M. Nogueras-Gonzalez, Lianchun Xiao, Amado J. Zurita, Sumit K. Subudhi, Shi Ming Tu, Ana M. Aparicio, Cristian Coarfa, Kimal Rajapakshe, Shixia Huang, Nora M. Navone, Sue Hwa Lin, Guocan Wang, Sumankalai Ramachandran, Mark A. Titus, Theocharis Panaretakis, Gary E. Gallick, Eleni Efstathiou, Patricia TroncosoChristopher Logothetis

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients and Methods: Patients received ADT plus cabozantinib starting at 60 mg daily. The primary endpoint was castrate-resistant PFS by radiographic criteria, clinical progression, or receipt of additional therapy. Secondary endpoints included OS, safety, radiographic responses, and biomarker modulation. Results: Sixty-two patients received treatment. With a median follow-up of 31.2 months, the mPFS was 16.1 months (95% CI, 14.6-22.7 months), and mOS was not reached. Reductions in PSA ≽ 90%, bone-specific alkaline phosphatase ≽ 50%, and urine N-telopeptides ≽ 50% occurred in 83%, 87%, and 86% of evaluable patients, respectively. Responses in bone scan and measurable disease were observed in 81% of and 90% of evaluable patients, respectively. Most common grade 3 adverse events were hypertension (19%), diarrhea (6%), and thromboembolic events (6%), and dose reductions occurred in 85% of patients. Analysis of baseline cytokine and angiogenic factors (CAFs) revealed that higher plasma concentrations of Lumican, CXCL5, CD25, and CD30 were associated with shorter PFS as was high tumor expression of pFGFR1. Conclusions: Cabozantinib plus ADT has promising clinical activity in HNMPCa. CAF profiles and tissue markers suggest candidate prognostic and predictive markers of cabozantinib benefit and provide insights for rational therapy combinations.

Original languageEnglish (US)
Pages (from-to)990-999
Number of pages10
JournalClinical Cancer Research
Issue number5
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

MD Anderson CCSG core facilities

  • Biostatistics


Dive into the research topics of 'A phase II study of cabozantinib and androgen ablation in patients with hormone-naïve metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this